Clinical OMICS

JAN-FEB 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 45 of 47

44 Clinical OMICs January/February 2017 Industry Events Molecular Med Tri-Con February 19–24, San Francisco The Molecular Medicine Tri-Conference, now in its 24th year, attracts more than 3,500 drug discovery and devel- opment professionals from more than 40 countries. Since its founding, the Tri-Conference has grown into a diverse event, focusing on molecular medicine, specifically on dis- covery, genomics, diagnostics, and information technol- ogy. The educational program will feature more than 400 presentations and panel discussions, 30 roundtable dis- cussions, and the presentation of more than 170 scientific posters. To help attendees stay abreast of the latest products and technology in the market, the exhibit hall features 200+ companies. Precision: Breast Cancer Summit March 7–8, Cambridge, MA Breast cancer R&D receives the largest amount of spending across all cancer types, and represents the largest opportu- nity for developers. Precision: Breast Cancer World Summit will bring together senior scientists and business lead- ers from pharma, biotech, and academia, and will feature a variety of networking sessions designed to encourage meaningful collaborations. The summit will cover the latest updates from the pipelines of small and large drug devel- opers, and feature discussions around the latest trends in precision medicine through case studies from early discov- ery to development. Select topics include: Antibody Drug Conjugates, Immuno-Oncology, and Biomarkers/Compan- ion Diagnostics. Biomarker Summit March 20–22, San Diego The Biomarker Summit is a meeting place for leaders in the field to discuss the issues and challenges scientists and researchers face in all aspects of the biomarker and diag- nostic development process from discovery to translation to commercialization. A wide variety of topics will be cov- ered including biomarker identification, validation and translation strategies, bioinformatics and systems biology approaches to personalized medicine, big data analytics and management, regulatory and reimbursement trends, com- panion diagnostics development, and much more. Through scientific presentations, case studies, and panel discussions, these areas will be addressed in an intimate and highly inter- active environment with perspectives from industry, aca- demia, and the public sector. Assembling leading scientists, researchers, decision-makers, and other players across the industry spectrum, the summit provides a unique opportu- nity to learn about the latest biomarker developments in the four major therapeutic areas of oncology, neurology, cardio- vascular, and inflammation and immunology. AACR Annual Meeting April 1–5, Washington, DC The AACR Annual Meeting, organized by the American Association for Cancer Research, highlights the best cancer science and medicine from institutions all over the world. Attendees are invited to stretch their boundaries, form collaborations, attend sessions outside their own areas of expertise, and learn how to apply new concepts, tools, and techniques to their own research. The meeting will feature more than 600 abstracts, 200 plus presentations and will be attended by roughly 18,000 members of the cancer research community from around the globe. Plenary sessions will include new approaches to detecting cancer, immunology, precision medicine, and computational approaches to can- cer research. Other sessions feature recent advances in diag- nostics and therapeutic research, organ site research, and prevention research, as well as science policy and science regulatory policy. aurielaki / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2017